Almirall licenses IL-21 antibody from Novo Nordisk
Pharmaceutical Technology
FEBRUARY 19, 2024
Almirall has signed a licensing agreement for the acquisition of worldwide rights to Novo Nordisk’s IL21-hindering antibody NN-8828.
Pharmaceutical Technology
FEBRUARY 19, 2024
Almirall has signed a licensing agreement for the acquisition of worldwide rights to Novo Nordisk’s IL21-hindering antibody NN-8828.
Pharmaceutical Technology
APRIL 18, 2024
Discover how Vir Biotechnology's patented multispecific antibodies target distinct Zika virus epitopes, neutralizing ZIKV infection. Explore the innovative potential for prophylaxis and treatment in this groundbreaking patent.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
APRIL 4, 2024
Discover Xencor Inc's groundbreaking patent for novel GPC3 binding domains and bispecific antibodies targeting GPC3-associated cancers. Explore the innovative method for manufacturing these antibodies and their potential in cancer treatment.
Bio Pharma Dive
MAY 25, 2023
A pair of dual-acting antibodies displayed early potential to become a new type of drug regimen for the blood cancer, but led to a high rate of side effects as well.
Pharmaceutical Technology
APRIL 18, 2024
Explore the innovative fusion polypeptide with IL-2 and antibody Fc region, revolutionizing T cell activity modulation. Discover Cue Biopharma's groundbreaking patent for variant immunomodulatory polypeptides and fusion polypeptides, including T-cell modulatory multimeric polypeptides.
Pharmaceutical Technology
APRIL 15, 2024
Discover Genzyme Corp's innovative method for detecting anti-drug antibodies in human body fluids. Learn how their patented process reduces interference in drug assays effectively.
Pharmaceutical Technology
MARCH 7, 2024
Gilead Sciences has entered an agreement with Merus for the discovery of dual tumour-associated antigens targeting trispecific antibodies.
Let's personalize your content